Showing 1-10 of about 240 articles.
OXiGENE, Inc.
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that enrollment has been completed in a randomized Phase 2 clinical trial testing the combination of ZYBRESTAT® (fosbretabulin; CA-4P) plus bevacizumab to treat patients with advanced ovarian cancer. This trial, GOG-0186I, is being conducted by the Gynecologic Oncology Group (GOG) under the sponsorship of Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). This is the first and currently the only randomized trial to test an antiangiogenic therapeutic agent combined with a vascular disrupting agent in ovarian cancer, without including any cytotoxic chemotherapy. The fosbretabulin tromethamine is being provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE and the bevacizumab is being provided under a CRADA with Genentech, Inc.
OXiGENE, Inc.
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2013 results on Monday, May 6, 2013. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
OXiGENE, Inc.
OXiGENE Announces $5 Million Private Placement
SOUTH SAN FRANCISCO, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has entered into definitive agreements with institutional accredited investors in a private placement of $5.0 million of zero coupon convertible preferred stock (which are convertible into a total of approximately 1.38 million shares of common stock) and 2 series of warrants potentially exercisable for up to approximately 2.76 million additional shares of common stock, in the aggregate. In addition to the preferred stock not having a required dividend right, the preferred stock will not have any preferences over the Company's common stock, including liquidation rights. Subject to certain ownership limitations, the preferred stock is convertible at any time at the option of the holder into shares of common stock at a conversion price of $3.63 (which represents a price above the closing price of the common stock on the previous trading day). The first series of warrants will allow for the investors to purchase up to approximately 1.38 million shares of common stock at an exercise price of $3.40 per share and are exercisable for 5 years. The second series of warrants will allow for the investors to purchase up to approximately 1.38 million shares of common stock at an exercise price of $3.40 per share and are exercisable for 2 years. OXiGENE has agreed to register the resale of the shares of common stock issuable upon conversion of the preferred stock and upon exercise of the warrants.
OXiGENE, Inc.
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents
SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the US Patent and Trademark Office issued U.S. Patent No. 8,397,859, covering certain benzosuberene-based compounds, including the analogues referred to as KGP18 and KGP156 that are currently in preclinical development. The patent also covers methods of using those compounds to inhibit tubulin polymerization, to reduce blood flow to a tumor, or to restrain, slow, stop or reverse progression of a tumor.
OXiGENE, Inc.
OXiGENE Reports Full Year 2012 Financial Results
SOUTH SAN FRANCISCO, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2012.
OXiGENE, Inc.
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast
SOUTH SAN FRANCISCO, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2012 results on Tuesday, March 12, 2013. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
OXiGENE, Inc.
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the randomized Phase 2 study evaluating the combination of ZYBRESTAT® (fosbretabulin tromethamine or CA4P) and Avastin® (bevacizumab) to treat patients with persistent or recurrent ovarian cancer has again demonstrated acceptable tolerability in the second and final scheduled interim toxicity analysis. As specified in the study protocol, no additional pre-specified safety concerns were observed, according to a meeting of the study's Safety Review Committee (SRC). OXiGENE anticipates that patient accrual for the study will be completed within the next 3-4 months, and that top-line data will be available at the end of the year.
OXiGENE, Inc.
OXiGENE Announces Presentation at BIO CEO Conference on February 12th
SOUTH SAN FRANCISCO, Calif., Feb. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 15th annual BIO-CEO & Investor conference on February 12, 2013 at 3:30 pm ET at the Waldorf Astoria Hotel in New York City.
OXiGENE, Inc.
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appointed to its board of directors. Dr. Chaplin formerly served as chief scientific officer and head of research and development at OXiGENE, and more recently has been a scientific advisor to the company. Dr. Chaplin has more than 30 years in oncology research and drug development, and is known and respected worldwide for his pioneering work in the field of vascular disrupting technologies.
Showing 1-10 of about 240 articles.